Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer

por Willemsen, A. E. C. A. B., Knapen, L. M., de Beer, Y. M., Brüggemann, R. J. M., Croes, S., van Herpen, C. M. L., van Erp, N. P.
Publicado 2017

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

por Schneider, T. C., de Wit, D., Links, T. P., van Erp, N. P., van der Hoeven, J. J. M., Gelderblom, H., van Wezel, T., van Eijk, R., Morreau, H., Guchelaar, H. J., Kapiteijn, E.
Publicado 2015

Myelosuppression by sunitinib is flt-3 genotype dependent

por van Erp, N P, Mathijssen, R H J, van der Veldt, A A, Haanen, J B, Reyners, A K L, Eechoute, K, Boven, E, Wessels, J A M, Guchelaar, H-J, Gelderblom, H
Publicado 2010

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs

por Overbeek, J.K., Heine, R. ter, Verheul, H.M.W., Chatelut, E., Rudek, M.A., Gurney, H., Plummer, R., Gilbert, D.C., Buclin, T., Burger, D.M., Bloemendal, H.J., van Erp, N.P.
Publicado 2023

Everolimus pharmacokinetics and its exposure–toxicity relationship in patients with thyroid cancer

por de Wit, D., Schneider, T. C., Moes, D. J. A. R., Roozen, C. F. M., den Hartigh, J., Gelderblom, H., Guchelaar, H. J., van der Hoeven, J. J., Links, T. P., Kapiteijn, E., van Erp, N. P.
Publicado 2016